De Fazio Luigia, Cavazza Elena, Spisni Enzo, Strillacci Antonio, Centanni Manuela, Candela Marco, Praticò Chiara, Campieri Massimo, Ricci Chiara, Valerii Maria Chiara
Luigia De Fazio, Elena Cavazza, Enzo Spisni, Antonio Strillacci, Maria Chiara Valerii, Department of Biological, Geological and Environmental Sciences, Biology Unit, University of Bologna, Via Selmi 3, 40126 Bologna, Italy.
World J Gastroenterol. 2014 Feb 28;20(8):2051-61. doi: 10.3748/wjg.v20.i8.2051.
To characterize longitudinally the inflammation and the gut microbiota dynamics in a mouse model of dextran sulfate sodium (DSS)-induced colitis.
In animal models, the most common method used to trigger colitis is based on the oral administration of the sulfated polysaccharides DSS. The murine DSS colitis model has been widely adopted to induce severe acute, chronic or semi-chronic colitis, and has been validated as an important model for the translation of mice data to human inflammatory bowel disease (IBD). However, it is now clear that models characterized by mild intestinal damage are more accurate for studying the effects of therapeutic agents. For this reason, we have developed a murine model of mild colitis to study longitudinally the inflammation and microbiota dynamics during the intestinal repair processes, and to obtain data suitable to support the recovery of gut microbiota-host homeostasis.
All plasma cytokines evaluated, except IL-17, began to increase (P < 0.05), after 7 d of DSS administration. IL-17 only began to increase 4 d after DSS withdrawal. IL-1β and IL-17 continue to increase during the recovery phase, even when clinical signs of colitis had disappeared. IL-6, IL-10 and IFN-γ reached their maxima 4 d after DSS withdrawal and decreased during the late recovery phase. TNFα reached a peak (a three- fold increase, P < 0.05), after which it slightly decreased, only to increase again close to the end of the recovery phase. DSS administration induced profound and rapid changes in the mice gut microbiota. After 3 d of DSS administration, we observed a major reduction in Bacteroidetes/Prevotella and a corresponding increase in Bacillaceae, with respect to control mice. In particular, Bacteroidetes/Prevotella decreased from a relative abundance of 59.42%-33.05%, while Bacillaceae showed a concomitant increase from 2.77% to 10.52%. Gut microbiota rapidly shifted toward a healthy profile during the recovery phase and returned normal 4 d after DSS withdrawal. Cyclooxygenase 2 expression started to increase 4 d after DSS withdrawal (P < 0.05), when dysbiosis had recovered, and continued to increase during the recovery phase. Taken together, these data indicated that a chronic phase of intestinal inflammation, characterized by the absence of dysbiosis, could be obtained in mice using a single DSS cycle.
Dysbiosis contributes to the local and systemic inflammation that occurs in the DSS model of colitis; however, chronic bowel inflammation is maintained even after recovery from dysbiosis.
纵向表征葡聚糖硫酸钠(DSS)诱导的小鼠结肠炎模型中的炎症和肠道微生物群动态变化。
在动物模型中,引发结肠炎最常用的方法是口服硫酸化多糖DSS。小鼠DSS结肠炎模型已被广泛用于诱导严重急性、慢性或半慢性结肠炎,并已被验证为将小鼠数据转化为人类炎症性肠病(IBD)的重要模型。然而,现在很清楚,以轻度肠道损伤为特征的模型在研究治疗药物的效果方面更准确。因此,我们开发了一种轻度结肠炎小鼠模型,以纵向研究肠道修复过程中的炎症和微生物群动态变化,并获得适合支持肠道微生物群-宿主稳态恢复的数据。
除IL-17外,所有评估的血浆细胞因子在给予DSS 7天后开始增加(P<0.05)。IL-17仅在停用DSS 4天后开始增加。即使结肠炎的临床症状已经消失,IL-1β和IL-17在恢复阶段仍继续增加。IL-6、IL-10和IFN-γ在停用DSS 4天后达到最大值,并在恢复后期下降。TNFα达到峰值(增加了三倍,P<0.05),之后略有下降,仅在恢复阶段接近结束时再次增加。给予DSS导致小鼠肠道微生物群发生深刻而迅速的变化。与对照小鼠相比,给予DSS 3天后,我们观察到拟杆菌属/普雷沃菌属显著减少,芽孢杆菌科相应增加。特别是,拟杆菌属/普雷沃菌属的相对丰度从59.42%降至33.05%,而芽孢杆菌科则从2.77% concomitant增加到10.52%。在恢复阶段,肠道微生物群迅速向健康状态转变,并在停用DSS 4天后恢复正常。环氧合酶2表达在停用DSS 4天后开始增加(P<0.05),此时生态失调已恢复,并在恢复阶段持续增加。综上所述,这些数据表明,使用单个DSS周期可在小鼠中获得以无生态失调为特征的肠道炎症慢性期。
生态失调促成了DSS结肠炎模型中发生的局部和全身炎症;然而,即使从生态失调中恢复后,慢性肠道炎症仍会持续。